PMID- 26194362
OWN - NLM
STAT- MEDLINE
DCOM- 20170309
LR  - 20181202
IS  - 1473-1150 (Electronic)
IS  - 1470-269X (Linking)
VI  - 16
IP  - 4
DP  - 2016 Aug
TI  - Paradoxical psoriasiform reactions to anti-TNFalpha drugs are associated with genetic 
      polymorphisms in patients with psoriasis.
PG  - 336-40
LID - 10.1038/tpj.2015.53 [doi]
AB  - Paradoxical psoriasiform reactions to anti-tumor necrosis factor alpha (TNFalpha) agents 
      have been described. We aimed to study the association between these reactions 
      and polymorphisms in genes previously associated with psoriasis or other 
      autoimmune diseases. A total of 161 patients with plaque-type psoriasis treated 
      with anti-TNFalpha drugs were genotyped for 173 single-nucleotide polymorphisms 
      (SNPs) using the Illumina Veracode genotyping platform. Among the 161 patients, 
      25 patients developed a paradoxical psoriasiform reaction consisting of a change 
      in morphology, mostly to guttate psoriasis (88%). These lesions developed 
      9.20+/-13.52 months after initiating treatment, mainly with etanercept (72%). 
      Psoriasis type and a Psoriasis Area and Severity Index (PASI) 75 response to 
      treatment were not associated with lesions. Multivariate logistic regression 
      revealed that five SNPs (rs11209026 in IL23R, rs10782001 in FBXL19, rs3087243 in 
      CTLA4, rs651630 in SLC12A8 and rs1800453 in TAP1) were associated with 
      paradoxical reactions. This is the first study to show an association between 
      genetic polymorphisms and paradoxical reactions in patients with psoriasis 
      treated with anti-TNFalpha drugs.The Pharmacogenomics Journal advance online 
      publication, 21 July 2015; doi:10.1038/tpj.2015.53.
FAU - Cabaleiro, T
AU  - Cabaleiro T
AD  - Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto 
      Teofilo Hernando, Instituto de Investigacion Sanitaria Princesa (IP), Madrid, 
      Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas 
      (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Prieto-Perez, R
AU  - Prieto-Perez R
AD  - Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto 
      Teofilo Hernando, Instituto de Investigacion Sanitaria Princesa (IP), Madrid, 
      Spain.
FAU - Navarro, R
AU  - Navarro R
AD  - Dermatology Service, Hospital Universitario de la Princesa, Instituto Teofilo 
      Hernando, Instituto de Investigacion Sanitaria Princesa (IP), Madrid, Spain.
FAU - Solano, G
AU  - Solano G
AD  - Dermatology Service, Hospital Universitario de la Princesa, Instituto Teofilo 
      Hernando, Instituto de Investigacion Sanitaria Princesa (IP), Madrid, Spain.
FAU - Roman, M
AU  - Roman M
AD  - Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto 
      Teofilo Hernando, Instituto de Investigacion Sanitaria Princesa (IP), Madrid, 
      Spain.
FAU - Ochoa, D
AU  - Ochoa D
AD  - Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto 
      Teofilo Hernando, Instituto de Investigacion Sanitaria Princesa (IP), Madrid, 
      Spain.
FAU - Abad-Santos, F
AU  - Abad-Santos F
AD  - Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto 
      Teofilo Hernando, Instituto de Investigacion Sanitaria Princesa (IP), Madrid, 
      Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas 
      (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Dauden, E
AU  - Dauden E
AD  - Dermatology Service, Hospital Universitario de la Princesa, Instituto Teofilo 
      Hernando, Instituto de Investigacion Sanitaria Princesa (IP), Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150721
PL  - United States
TA  - Pharmacogenomics J
JT  - The pharmacogenomics journal
JID - 101083949
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 2)
RN  - 0 (CTLA-4 Antigen)
RN  - 0 (CTLA4 protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Dermatologic Agents)
RN  - 0 (F-Box Proteins)
RN  - 0 (FBXL19 protein, human)
RN  - 0 (IL23R protein, human)
RN  - 0 (Receptors, Interleukin)
RN  - 0 (TAP1 protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 2/genetics
MH  - Adult
MH  - Aged
MH  - CTLA-4 Antigen/genetics
MH  - DNA-Binding Proteins/genetics
MH  - Dermatologic Agents/*adverse effects
MH  - Drug Eruptions/diagnosis/*genetics
MH  - F-Box Proteins/genetics
MH  - Female
MH  - Genetic Association Studies
MH  - Genotype
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Pharmacogenomic Testing
MH  - Pharmacogenomic Variants/*genetics
MH  - Phenotype
MH  - *Polymorphism, Single Nucleotide
MH  - Predictive Value of Tests
MH  - Psoriasis/*drug therapy/immunology
MH  - Receptors, Interleukin/genetics
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology
EDAT- 2015/07/22 06:00
MHDA- 2017/03/10 06:00
CRDT- 2015/07/22 06:00
PHST- 2015/03/11 00:00 [received]
PHST- 2015/05/26 00:00 [revised]
PHST- 2015/06/03 00:00 [accepted]
PHST- 2015/07/22 06:00 [entrez]
PHST- 2015/07/22 06:00 [pubmed]
PHST- 2017/03/10 06:00 [medline]
AID - tpj201553 [pii]
AID - 10.1038/tpj.2015.53 [doi]
PST - ppublish
SO  - Pharmacogenomics J. 2016 Aug;16(4):336-40. doi: 10.1038/tpj.2015.53. Epub 2015 
      Jul 21.